Upload
alexia-sherman
View
236
Download
0
Tags:
Embed Size (px)
Citation preview
scil
ArtisanArtisan Coral BioNetCoral BioNet
Scil Finance Holding GmbHScil Finance Holding GmbH
Scil Technology Holding GmbHScil Technology Holding GmbH
ScilAnimal Care
ScilAnimal Care
ScilDiagnostics
ScilDiagnostics
ScilBiomedicals
ScilBiomedicals
ScilProteins
ScilProteins
BioNetLaboratories
Asia Diagnostics
BioNetLaboratories
Asia Diagnostics
The SCIL Group
Stefan Engelhorn
20 % 80 %
scil
Scil Technology Holding
• Use niches in Life Science to develop, manufacture and marketinnovative diagnostics and therapeutics
• Use investment possibilities to synergize the existing operativebusiness
• Bridge the gap between VC funded companies and big pharmaby using professional industrial development know how
• Create profit along the value chain for our partners and ourselves
scil
Scil Technology Holding: ObjectivesShort term (3 years):
Focus on industrial know how to develop and market productsin diagnostics to generate short term cash flow.Partnerships with VC funded companies for co-development of innovative protein pharmaceuticals.
Medium term (3 - 6 years):
Project pipeline for innovative diagnostics and protein pharmaceuticalsfocussed on niche indications. Co-development and co-marketingof protein pharmaceuticals and innovative diagnostics products.
Long term (> 6 years):
Use the synergistic potential of diagnostic and therapeutic activitiesto create integrated solutions for more efficient treatments in nicheindications
scil
Scil Technology Holding: Competencies
An one year old privately owned company which is actively involved in the development and marketing of diagnostics and therapeutics
Diagnostics• proprietary immunoassay technology and data transfer concept• innovative reagent packaging concept• sales organizations in Europe and Asia (Singapore)• food testing products
Therapeuticsfocus on the development of therapeutic proteins• anti-L-selectin : prevention of polytrauma clinical phase II• immunotoxin MDX-RA : prevention of secondary cataract (partner Medarex) clinical phase III• bispec. antibody MDX-210: treatment of prostate cancer (partner Medarex) clinical phase Ib
Use the synergistic potential of diagnostics and therapeuticsto create integrated health care concepts for niche indications
scil
Scil Group: Management TeamS. Engelhorn, Ph.D., M.D.
G. Schumacher, Ph.D.
J. Bornemann
C. Dony, Ph.D.
J. Feuerstein, Ph.D.
R. Schenk, Ph.D.
U. Martin, M.D.
CEO of Scil Finance Holding. President of Scil Technology Holding. Member and chairman of several trusts
CEO of Scil Technology Holding. 20 years of industrial experience in diagnostics and therapeutics. Former head of R&D at BM/Roche
Vice President, CFO of Scil Technology Holding. Former at KPMG, tax consultant and commercial director at Gebr. März AG and Leonard Moll AG.
Vice President, Research and Development of Scil Technology Holding.Former head of musculoskeletal disorders at BM/Roche, scientist atGenentech Inc.
CEO of Scil Diagnostics. Former global strategic project planning at BM/Roche. Focus: marketing, PSO organization management, partnership management
CEO of Scil Diagnostics. Former head of system development and leaderproject lab diagnostics at BM/Roche. Focus: system and technology concepts and implementation
CEO of Scil Pharmaceuticals. Former head of pharmacology and cardiovascular research at BM/Roche and senior scientist at Hoechst
scil
Scil Biomedicals: Mission
Scil Biomedicals
is a young privately owned company with the mission to use
professional industrial drug-developmentknow how
to develop, manufacture and market innovativebio-pharmaceuticals
scil
Scil Biomedicals: Corporate Profile
Founded in May 1999
Privately owned company
Subsidiary of Scil Technology Holding GmbH
Focus: development of protein pharmaceuticals; innovative products for niche indications
- specific treatments for cancer and inflammation - tissue regeneration: ophthalmic, bone and cartilage
scil
Scil BioMedicals: Facilities and people
• Location in Martinsried/ Munich
• Employees: 10 people (20 people by mid of 2000)
• 700 square ft. lab space, Gründerzentrum Martinsried
• 9000 square ft. lab- and office-space (3/2000)
scil
Scil Biomedicals : Core Management TeamCEO
U. Martin
former head of pharmacology and cardiovascular research at BM/Roche; senior scientist at Hoechst
Pre-clinicalResearchC. Dony
Biotechnology
U. Kohnert
PharmaceuticalSciencesR. Seidl
Non-clinicalDevelopment
U. Martin
ClinicalDevelopment
M. Beckert
Former head ofmusculoskeletaldisorders R&Dat BM/Roche;scientist at Genentech
project leaderbiotechnology for reteplase, specialist inpreformulationat BM/Roche
Former head ofpharmacology,project leader: therap. Mab`s, gene therapyat BM/Roche
Former head ofclinical researchat MSD
Team of legal (B. Jurisch), patent (B. Huber) and diagnostic (A. Wahlefeld) advisors
Project leader quality controlat Mucos pharma
scil
Scil Biomedicals: Core Competence
Development of protein pharmaceuticals
from active compound
to approval
scil
Scil Biomedicals: Core CompetenceDevelopment of protein pharmaceuticals
Protein bulk drug
Finished product
Integrated technology platform for bulk drug and finished product- protein process development- formulation/drug delivery- pharmaceutical analyses
Pre-clinic bioanalytics
Clinical development
Regulatory affairs
Experienced steering of non-clinical and clinicaldevelopment activities including GMP manufacturingvia CROs
Team of project leaders with experience in inter-national project development and regulatory filing (FDA & EMEA for RapiLysin®/RetavaseTM)
Approval
scil
Scil Biomedicals: Fast track development of Anti-L-Selectin (BNP 001) in 1999Anti-L-selectin for the prevention of multi organ failure (partner: PDL) after polytrauma
January 15
February 24
March 31
June 2
June 4
July 14
July 28
November
LETTER OF INTENT: PDL - BioNet for anti-L-selectin
Start TECHNICAL TRANSFER (know how, reports and materials)
CONTRACT PDL - BioNet signed
CLINICAL DRUG SUPPLIES released
PHASE I: first in man
DOSE SELECTION FOR PHASE II
Submission of phase II study protocol to CENTRAL ETHICS COMMITTEE of PI
PHASE II (Polytrauma): “first patient in”
scil
Scil Biomedicals: Strategic Focus
• Development of innovative protein pharmaceuticals • Antibodies and growth factors as specific therapies
for niche indications
Oncology, (tumor specific therapies)
Inflammation (multi organ failure)
Eye disorders
bone and cartilage disorders
scil
Scil Biomedicals: Research & DevelopmentPipeline
• Immunotoxin MDX-RA prevention of secondary cataract (partner Medarex)
- clinical phase III - market entry 2003
• Anti-L-selectin prevention of multi organ failure after severe polytrauma (partner: PDL)- clinical phase II- market entry 2003/4
• Bispecific antibody MDX-210 late stage prostate cancer (partner Medarex) - clinical phase Ib - market entry 2005
• research on growth factors for tissue regeneration eg. bone and cartilage disorders
scil
Scil Proteins
is a young privately owned company with the mission to use
professional scientific and industrial protein production know how
to develop and manufacture pharmaceutical proteins
Scil Proteins: Mission
scil
Development of pharmaceutical proteins
from design to production
of an active protein
Scil Proteins: Core competence
scil
Scil Proteins: Core technologies
Technologies/Services:
• Small scale production of recombinant proteins
• Refolding of E. coli inclusion body proteins samples for: preclinical research
protein structure analysis
rationale drug design
• Protein binding Molecule Technology
scil
Scil Proteins: Core competenceDevelopment of pharmaceutical proteins
Recombinant
protein production
Pro- and eukaryotic expression systems
Fermentation 10l, 50l, 100l reactors
Refolding of proteins frominclusion bodies
Proteinpurification conventional methods, affinity techniques
Physicochemical characterization CD, fluorescence, mass spectroscopy, biacore
Customized protein
folding
Isolation of stable
binding proteins Screening of scaffold phage display libraries
scil
Scil Proteins: Facilities and people
Scil Proteins: People and facilities
• Location in Halle/Saale
• Scientific founder Prof. R. Rudolph, Inst. of Biotechnology, Halle
• Employees: 6 people (12 people by end of 2000)
• 1000 square foot lab- and office-space associated with the Institute for Biotechnology
(3/2000)
• 4200 square foot lab- and office-space “Gründerzentrum Halle” (10/2000)
scil
Scil Protein Technology Services: Core Competence
• Expression systems (pro- and eukaryotic organisms)
• Fermentation facilities: 10 l-, 50 l-, 100 l-reactors (E. coli)
• Highly specialized protein refolding technology - automaticprotein folding reactor for proteins expressed in inclusionbodies (E. coli)
• Proteinpurification: conventional methods and affinity techniquesto guarantee straight forward purification of protein samples
• Physicochemical characterized and proteinprofiling, massspectroscopy, CD, fluorescence/biacore, protein sequencing,etc.
scil
Scil Protein Technology ServicesProjects of the Institute of Protein Technologies: Prof. R. Rudolph, HalleSuccessful refolding of inclusion body proteins expressed in E. coli
Protein
GLP1-Receptorpro NGFpro BMP2PTH-ReceptorProteinase KEnterokinasePepsinogenProcollagen C Proteinaseh Phosphodiesterase PDE 4HIV ProteaseAntibody fragmentsCD 4Helicase
Partnership
Boehringer MannheimBoehringer MannheimRocheRocheRocheGenetics InstituteSchweizer Rotes Kreuz / NovartisPfizerUniversity Leipzig / AWDUniversity Halle---